Home
LEXX
LEXX News

Latest Lexaria Bioscience Corp. (LEXX) News on July 27, 2024

LEXX: GLP-1 Agonist Program Updates

Zacks Small Cap Research

4 days ago

LEXX: GLP-1 Agonist Program Updates

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

9 days ago

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

ACCESSWIRE

9 days ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Lexaria Preparing For Strategic Growth

ACCESSWIRE

10 days ago

Lexaria Preparing For Strategic Growth

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

ACCESSWIRE

17 days ago

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

MT Newswires

18 days ago

Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

ACCESSWIRE

18 days ago

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

MT Newswires

a month ago

Lexaria Bioscience Hires Contract Research Organization For 12-week Study

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

ACCESSWIRE

a month ago

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

MT Newswires

2 months ago

Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

ACCESSWIRE

2 months ago

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

ACCESSWIRE

2 months ago

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

MT Newswires

2 months ago

Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

ACCESSWIRE

2 months ago

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

ACCESSWIRE

2 months ago

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Simply Wall St.

3 months ago

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

ACCESSWIRE

3 months ago

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

ACCESSWIRE

3 months ago

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

ACCESSWIRE

3 months ago

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

LEXX: Begin with the End in Mind

Zacks Small Cap Research

3 months ago

LEXX: Begin with the End in Mind

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

ACCESSWIRE

3 months ago

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Lexaria Awarded New Patents

ACCESSWIRE

4 months ago

Lexaria Awarded New Patents

Newsfile

4 months ago

Lexaria to Present at The LD Micro Invitational XIV

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

ACCESSWIRE

4 months ago

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

ACCESSWIRE

5 months ago

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

ACCESSWIRE

5 months ago

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

ACCESSWIRE

5 months ago

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

ACCESSWIRE

5 months ago

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Simply Wall St.

5 months ago

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

5 months ago

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

5 months ago

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's Submits Investigational New Drug Application

ACCESSWIRE

6 months ago

Lexaria's Submits Investigational New Drug Application

Lexaria Releases Annual Letter from the CEO

ACCESSWIRE

6 months ago

Lexaria Releases Annual Letter from the CEO

LEXX’ Sweet Opportunity in GLP-1s

Zacks Small Cap Research

6 months ago

LEXX’ Sweet Opportunity in GLP-1s

Kentucky First Federal Bancorp Announces Suspension of Quarterly Cash Dividend

GlobeNewswire

6 months ago

Kentucky First Federal Bancorp Announces Suspension of Quarterly Cash Dividend

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

ACCESSWIRE

6 months ago

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

Why Fast-paced Mover Fathom Holdings (FTHM) Is a Great Choice for Value Investors

Zacks

6 months ago

Why Fast-paced Mover Fathom Holdings (FTHM) Is a Great Choice for Value Investors

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

GlobeNewswire

6 months ago

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

GlobeNewswire

7 months ago

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

GlobeNewswire

7 months ago

Aeries Technology to Participate at the 26th Annual ICR Conference

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

ACCESSWIRE

7 months ago

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

Argo Blockchain PLC Announces Total Voting Rights & Share Capital

ACCESSWIRE

7 months ago

Argo Blockchain PLC Announces Total Voting Rights & Share Capital

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

Simply Wall St.

7 months ago

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

CNW Group

7 months ago

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

Lexaria's Investigational New Drug Application Filing Update

ACCESSWIRE

8 months ago

Lexaria's Investigational New Drug Application Filing Update

PR Newswire

8 months ago

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

GuruFocus.com

8 months ago

Abacus Life Inc (ABL) Reports 20% Revenue Growth in Q3 2023

Abacus Life Reports Third Quarter 2023 Results

GlobeNewswire

8 months ago

Abacus Life Reports Third Quarter 2023 Results

GuruFocus.com

9 months ago

Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire

9 months ago

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

GlobeNewswire

9 months ago

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

GlobeNewswire

9 months ago

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Share on Social Networks: